A clinical evaluation of safety of combination therapy with Rapid Onset Opioid and Short Acting Opioid.

A clinical evaluation of safety of combination therapy with Rapid Onset Opioid and Short Acting Opioid. - A clinical evaluation of safety of combination therapy with ROO and SAO.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019224

Enrollment

Registered

2015-10-03

Start date

2015-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer Pain

Interventions

Breakthrough pain was managed with fentanyl buccal tablet and short-acting opioid. Breakthrough pain was managed with sublingual fentanyl and short-acting opioid.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with cancer-related persistent pain who was controlled. Patients who agreed to participate in the study and signed informed consent form.

Exclusion criteria

Exclusion criteria: 1. the hypersensitiveness to opioids 2. serious respiratory depression or serious chronic obstructive pulmonary disease 3. disturbance of consciousness or the lack of judgment ability 4. gastrointestinal obstruction 5. not applicable determined by the attending physician responsible for the trial.

Design outcomes

Primary

Measure	Time frame
Analgesic effects (NRS, STAS-J) Adverse effect rate	—

Secondary

Measure	Time frame
Efficacy rate	—

Countries

Japan

Contacts

Public ContactMotonao Kurahashi

Kansai Electric Power Hospital Department of Pharmacy

kurahashi.motonao@c3.kepco.co.jp06-6458-5821

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026